rBIO announced that it has completed all the required analytical characterizations of its insulin biosimilar, R-biolin. This positions the company to file for the 351(k) drug submission process — an abbreviated licensure pathway for biological products shown to be biosimilar to or interchangeable with an FDA-licensed reference product.
Read MoreCureLab Oncology’s DNA vaccine Elenagen, in combination with a proven chemotherapy, demonstrates promising clinical results against one of the deadliest forms of ovarian cancer.
Read MoreIt’s incredibly important to have a strong brand image and supporting story before you begin PR. Here are some of our recent branding and website success stories with some hugely promising science startups.
Read MoreGero is a cutting-edge biotechnology company dedicated to the mission of curing age-related human diseases and understanding, slowing, and even halting the aging process itself.
Read MoreCyclica will apply its AI-enabled drug discovery platform to discover new therapeutic options with the goal of expanding the range of accessible non-hormonal contraceptive choices for women in developing countries.
Read MoreTwo biotech leaders have embarked on a research project to streamline manufacturing of non-viral CRISPR gene editing components. Their goal is to improve the editing efficiency and cell viability of non-viral-based cell therapies.
Read MoreThe clinical benefits currently delivered for terminally ill patients in CureLab’s clinical trial are already exceeding the benefits of new drugs recently approved by the FDA.
Read MoreGenScript’s new GMP-grade GenExact™ single-stranded DNA (ssDNA) and GenWand™ closed-end linear double-stranded DNA (dsDNA) services enable new workflows
Read MoreAllelica and Invitae want to integrate lifesaving genomic information into breast cancer risk assessments — for the benefit all women
Read MoreOpalia hits a key go-to-market milestone by eliminating fetal bovine serum from its cell-based milk manufacturing process
Read MoreAllelica, the leader in Polygenic Risk Scoring, expands scientific advisory board
Read MoreZingPR and CubanEight, a top British PR firm with B2B and technology expertise, collaborated to drive numerous media stories about this important development in AI-assisted lung cancer detection and therapeutics.
Read More“… when Elenagen was added to the treatment regimen, all patients showed complete or partial regression of the primary tumor and associated metastases in the lungs, liver, lymph nodes, and bones.”
Read MoreOptellum’s strategic collaboration agreement with the Lung Cancer Initiative at Johnson & Johnson drives media interest across the board.
Read MoreThis latest patent makes it feasible for CureLab to commence clinical trials aimed at establishing the effectiveness of Elenagen™ and its product variations for treatment of several deadly neurodegenerative diseases.
Read MoreFor patients who have contracted COVID, CureLab Oncology intends to determine how Elenagen can be used to reduce mortality and life-threatening complications, and to shorten time to recovery.
Read More
